Publications by authors named "N F Meneveau"
Background: Although the benefit of supportive care in the postcancer period is now well demonstrated, its implementation in the patient journey remains challenging. This article describes the development, since 2015 and in routine care, of supportive postcancer care comprising a multidisciplinary rehabilitation programme (MRP) based on exercise for patients with early breast cancer.
Methods: As part of quality control, we reviewed all patient files since the programme was implemented.
Background: The optimal strategy in prosthetic heart valve thrombosis (PVT) remains controversial, with no randomized trials and conflicting observational data. We performed a systematic review and meta-analysis of evidence comparing systemic thrombolysis and cardiac surgery in PVT.
Methods And Results: We searched PubMed, the Cochrane Library, and Embase for studies on treatment strategies in patients with left-sided PVT since 2000.
Venous thromboembolism (VTE) is a common, serious condition that requires anticoagulation for at least three months to prevent recurrence and long-term complications. After this initial period, the decision to continue or stop anticoagulation depends on the balance between the risk of recurrent VTE and the risk of bleeding. Established guidelines suggest short-term anticoagulation for VTE caused by transient factors and indefinite anticoagulation for recurrent or cancer-associated VTE.
View Article and Find Full Text PDFArticle Synopsis
- Researchers started looking into using a special medicine called thrombolytic therapy to treat a serious condition called pulmonary embolism (PE) a few years after doctors first used a specific imaging test to diagnose it.
- In 1992, a doctor named Guy Meyer showed that using a medicine called alteplase helped patients with PE quickly feel better, but it also came with risks like serious bleeding.
- Now, ongoing studies like the PEITHO-3 trial are testing safer ways to use thrombolytics and other treatments for PE, focusing not just on saving lives, but also on how patients feel after recovery.
Context And Aims: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of prognostic criteria for long progression-free survival (PFS) is still an unmet medical need. In this study, we sought to determine potential prognostic criteria for long-term eribulin response in HER2-negative MBC.
View Article and Find Full Text PDF